First global guidance for HPV vaccination for cervical cancer prevention

March 17, 2017, American Society of Clinical Oncology
High grade dysplasia (carcinoma in situ) in the uterine cervix. The abnormal epithelium is extending into a mucus gland to the left of centre. This disease can progress to invasive cancer (squamous cell carcinoma) of the cervix. Credit: Haymanj/public domain

The American Society of Clinical Oncology (ASCO) today issued a clinical practice guideline on human papillomavirus (HPV) vaccination for the prevention of cervical cancer. This is the first guideline on primary prevention of cervical cancer that is tailored to multiple regions of the world with different levels of socio-economic and structural resource settings, offering evidence-based guidance to health care providers worldwide.

The guideline includes specific recommendations according to four levels of resource settings: basic, limited, enhanced and maximal. The levels pertain to financial resources of a country or region, as well as the development of its health system—including personnel, infrastructure and access to services. The guideline complements ASCO's two other global, resource-stratified guidelines on cervical cancer, also stratified to these four levels of resources.1,2

Key guideline recommendations:

In all environments and independent of the resource settings, two doses of human papillomavirus vaccine are recommended for girls ages 9 to 14 years, with an interval of at least 6 months and up to 12 to 15 months between doses.

Girls who are HIV positive should receive three doses.

For maximal and enhanced resource settings:

  • If girls are 15 years or older and have received their first dose before age 15, they may complete the two-dose series;
  • If they have not received the first dose before age 15, they should receive three doses;
  • In both scenarios vaccination may be given through age 26 years.

For limited and basic resource settings: if sufficient resources remain after vaccinating girls 9 to 14 years, girls who received one dose may receive additional doses between ages 15 and 26 years.

Vaccination of boys: in all settings, boys may be vaccinated, if there is at least a 50% coverage in priority female target population, sufficient resources, and such vaccination is cost effective.

Cervical cancer is the fourth most common cancer among women worldwide, with less developed regions suffering a disproportionate burden from the disease. In fact, 85% of cervical cancer diagnoses and 87% of cervical cancer deaths occur in less developed regions, including parts of Africa and Latin America.

"Because resource availability varies widely, both among and within countries, we need to adjust strategies to improve access to HPV vaccination everywhere," said Silvia de Sanjosé, MD, PhD, co-chair of the Expert Panel that developed the guideline and head of the Cancer Epidemiology Research Program at Institut Català d'Oncologia in Barcelona, Spain. "This guideline is unique in offering cervical cancer vaccination recommendations that can be adapted to different resource levels and we expect it to have a major impact on the global health community."

HPV infection causes virtually all cervical cancers in the world. Although it may also lead to genital warts and certain other cancers, cervical cancer is by far the most common severe condition related to HPV infection. Unlike other existing HPV vaccination guidelines, ASCO's guideline focuses on the use of HPV vaccination specifically for the prevention of .

"Although HPV vaccine has been around for more than a decade, the uptake of the vaccine has been less than ideal in many places, including in high-resource countries such as the United States," said Silvina Arrossi, PhD, co-chair of the Expert Panel that developed the guideline and an official and researcher at the Instituto Nacional del Cancer in Buenos Aires, Argentina. "As an organization of cancer doctors, ASCO continues to endorse HPV vaccination programs and efforts to help spare more women around the world from this very difficult cancer."

Guideline Methodology

The guideline recommendations were developed by a multinational and multidisciplinary panel of oncology, obstetrics/gynecology, public health, cancer control, epidemiology/biostatistics, health economics, behavioral/implementation science, and patient advocacy experts, including some of the world's foremost research leaders on HPV and HPV vaccines.

The Expert Panel reviewed relevant literature published from 1966 to 2015, including systematic reviews, existing guidelines, and cost-effective analyses. This guideline reinforces selected recommendations offered in the World Health Organization (WHO) guideline, Centers for Disease Control and Prevention (CDC) guidelines, National Advisory Committee on Immunization guideline (Canadian), German guidelines, and Immunise Australia guideline.

Explore further: American Cancer Society endorses HPV vaccine recommendations from CDC

More information: The Primary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Clinical Practice Guideline was published today in the Journal of Global Oncology, and is available at www.asco.org/rs-cervical-cance … imary-prev-guideline along with supplementary materials.

1. Jeronimo J, et al. Secondary Prevention of Cervical Cancer: ASCO Resource-Stratified Clinical Practice Guideline. Journal of Global Oncology - published online before print October 28, 2016

2. Chuang LT, et al. Management and Care of Women With Invasive Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Clinical Practice Guideline. Journal of Global Oncology 2, no. 5 (October 2016) 311-340.

Related Stories

American Cancer Society endorses HPV vaccine recommendations from CDC

July 19, 2016
The American Cancer Society (ACS) has endorsed HPV vaccination recommendations from the CDC's Advisory Committee on Immunization Practices (ACIP), the principal source of guidance on U.S. immunization policy. The ACS's updated ...

American Cancer Society endorses two-dose regimen for HPV vaccination

February 7, 2017
The American Cancer Society has endorsed updated recommendations on human papillomavirus (HPV) vaccination from the Advisory Committee on Immunization Practices (ACIP) supporting a two-dose schedule for boys and girls who ...

Study finds not all women get appropriate care for cervical cancer

March 2, 2017
Women with locally advanced cervical cancer whose treatment follows national guidelines for care have better survival, regardless of race, ethnicity or stage of cancer.

Recommendations for secondary prevention of cervical cancer

October 25, 2016
(HealthDay)—In a Clinical Practice Guideline published online Oct. 12 in the Journal of Global Oncology, recommendations are presented for the secondary prevention of cervical cancer.

HPV vaccine reduced cervical abnormalities in young women

July 4, 2016
Young women who received the human papillomavirus (HPV) vaccine through a school-based program had fewer cervical cell anomalies when screened for cervical cancer, found a new study in CMAJ (Canadian Medical Association Journal).

Screening, HPV vaccine can prevent cervical cancer: FDA

February 8, 2017
(HealthDay)—Women can reduce their risk of cervical cancer through vaccination and screening, the U.S. Food and Drug Administration says.

Recommended for you

Single-cell study in a childhood brain tumor affirms the importance of context

April 20, 2018
In defining the cellular context of diffuse midline gliomas, researchers find the cells fueling their growth and suggest a potential approach to treating them: forcing their cells to be more mature.

Aggressive breast cancer already has resistant tumour cells prior to chemotherapy

April 20, 2018
Difficult to treat and aggressive "triple-negative" breast cancer is chemoresistant even before chemotherapy begins, a new study by researchers from Karolinska Institutet and the University of Texas MD Anderson Cancer Center ...

Mechanism that drives development of liver cancer brought on by non-alcoholic fatty liver disease discovered

April 19, 2018
A team of researchers from several institutions in China has found a mechanism that appears to drive the development of a type of liver cancer not caused by alcohol consumption. In their paper published in the journal Science ...

Discovery adds to evidence that some children are predisposed to develop leukemia

April 19, 2018
St. Jude Children's Research Hospital researchers have made a discovery that expands the list of genes to include when screening individuals for possible increased susceptibility to childhood leukemia. The finding is reported ...

Chip-based blood test for multiple myeloma could make bone biopsies a relic of the past

April 19, 2018
The diagnosis and treatment of multiple myeloma, a cancer affecting plasma cells, traditionally forces patients to suffer through a painful bone biopsy. During that procedure, doctors insert a bone-biopsy needle through an ...

Scientists identify 170 potential lung cancer drug targets using unique cellular library

April 19, 2018
After testing more than 200,000 chemical compounds, UT Southwestern's Simmons Cancer Center researchers have identified 170 chemicals that are potential candidates for development into drug therapies for lung cancer.

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

Cave_Man
not rated yet Mar 18, 2017
Hasn't it been proven already that the HPV vaccine is a huge fail and harms many people more so than helping?

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.